Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort

作者：Qi Jiang, Weizhen Liu, Xiangyu Zeng, Chenggang Zhang, Yuqiang Du, Liwu Zeng, Yuping Yin, Jun Fan, Ming Yang, Kaixiong Tao, Peng Zhang · 发表于：Frontiers in Immunology · 年份：2023 · DOI：10.3389/fimmu.2023.1122121 · 被引用次数：34 · 研究领域：Gastric Cancer Management and Outcomes、Esophageal Cancer Research and Treatment、Cancer Immunotherapy and Biomarkers

Objectives Immunotherapy plus chemotherapy has recently been applied in the neoadjuvant treatment for locally advanced gastric cancer (LAGC), while its superiority over neoadjuvant chemotherapy (NACT) alone remains to be explored. This study explored the safety and efficacy of NACT plus tislelizumab in patients with LAGC. Methods The data on patients with LAGC who received NACT combined with radical gastrectomy and NACT plus tislelizumab followed by radical gastrectomy was retrospectively collected. Clinicopathological characteristics of the two groups were compared. Results A total of 119 and 50 patients with gastric cancer treated with NACT and NACT plus tislelizumab, respectively, were enrolled. No significant difference was found between the baseline data of the two groups. The operative time (210.5 ± 70.4 min vs. 237.6 ± 68.4 min, P =0.732), intraoperative blood loss (157.8 ± 75.9 ml vs. 149.1 ± 92.5 ml, P =0.609), and number of dissected lymph nodes (24.7 ± 9.3 vs. 28.1 ± 10.3, P =0.195) was not statistically different between the two groups. In comparison to the NACT plus tislelizumab group, the R0 resection rate (100% vs. 89.9%, P =0.019) and pathologic complete response rate (26.0% vs. 3.4%, P <0.001) were significantly lower in the NACT group. The postoperative complication rates were 24.4% and 26.0% in the NACT and NACT plus tislelizumab groups with no significant difference (P =0.823). In subgroup analysis, tumor regression grade (TRG) (TRG 3: 72.3% vs. 23....